Human fibrinogen - Shanxi Kangbao Biological Product

Drug Profile

Human fibrinogen - Shanxi Kangbao Biological Product

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Shanxi Kangbao Biological Product
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Afibrinogenaemia

Most Recent Events

  • 15 Jan 2016 Clinical trials in Afibrinogenaemia in China (IV) prior to January 2016 (Shanxi Kangbao Biological Product pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top